Lantern Pharma Inc.'s SEC filings document a clinical-stage oncology company built around AI-enabled drug development, its RADR platform and related research technologies. The filings include Form 8-K reports for financial results, Regulation FD presentations, and demonstrations of withZeta.ai, including platform capabilities, commercial architecture, rare-cancer research applications and revenue strategy disclosures.
Proxy and annual-meeting filings cover board elections, equity incentive plan matters, option repricing, independent auditor ratification and stockholder voting results. The filing record also includes exhibit-based press releases and presentations, Inline XBRL cover data, and forward-looking-statement risk language tied to Lantern Pharma's clinical programs, AI platforms, capital needs and development-stage biotechnology operations.
Lantern Pharma Inc. is asking stockholders to vote at its December 1, 2026 annual meeting on seven matters: electing six directors; increasing authorized common stock from 25 million to 50 million shares; adding 250,000 shares to the equity plan; and approving issuance of up to 3,669,725 common shares upon exercise of Purchase Warrants. Other proposals cover auditor ratification and advisory votes on named executive compensation and its frequency; the Board recommends “one year” for the frequency vote.
As of October 5, 2026, 14,935,576 common shares were outstanding, with 281,597 authorized shares unissued and unreserved. The authorization amendment would not immediately dilute existing holders, though Lantern says future issuances may dilute earnings per share and stockholders’ equity or voting rights. The plan increase is subject to stockholder approval. The Purchase Warrants have a $1.09 exercise price and cannot be exercised until stockholders approve the share issuance; if approved, they expire five years after that approval.
Lantern Pharma Inc. (LTRN) received a Nasdaq notice that its common stock did not meet the $35,000,000 minimum market value of listed securities requirement after its market value stayed below that level for 30 consecutive business days. Nasdaq also said the company did not meet requirements under Listing Rules 5550(b)(1) and 5550(b)(3).
Lantern Pharma has 180 calendar days following the September 25, 2026 notice, through March 24, 2027, to regain compliance. If it seeks compliance through the market-value requirement, its market value must close at $35,000,000 or more for a minimum of 10 consecutive business days during that period. If the company does not regain compliance, it expects Nasdaq would notify it that its securities are subject to delisting from the Nasdaq Capital Market.
Lantern Pharma Inc. (LTRN) closed a registered direct offering on September 30, 2026, selling 1,469,725 common shares at $1.09 each and issuing pre-funded warrants for up to 2,200,000 shares at $1.0899 each. The company reported approximately $4.0 million in gross proceeds before placement-agent fees and other offering expenses; net proceeds are intended for working capital and general corporate purposes.
In a concurrent private placement, Lantern issued unregistered warrants for up to 3,669,725 shares at a $1.09 exercise price, potentially producing approximately $4 million in additional gross proceeds if fully exercised for cash. Exercise requires stockholder approval, and the warrants expire five years following the initial exercise date. They carry a 4.99% beneficial-ownership limit, or 9.99% at a holder’s election; an increase takes effect on the 61st day after election. Rodman & Renshaw acted as sole placement agent; Lantern paid a 7% cash fee on gross offering proceeds and issued placement-agent warrants to purchase 5% of the common shares or pre-funded warrants sold.
Lantern Pharma Inc. (LTRN) is offering 1,469,725 common shares at $1.09 each and, for qualifying purchasers in lieu of shares, pre-funded warrants to purchase up to 2,200,000 shares at $1.0899 per warrant; the underlying shares are also registered. The pre-funded warrants carry a $0.0001 exercise price and are immediately exercisable, with a 4.99% beneficial-ownership limit (or 9.99% at the holder’s election).
Lantern estimates net proceeds of approximately $3.60 million after placement-agent fees and estimated expenses, assuming the sale of all common shares offered and no exercise of purchase warrants; it intends to use the proceeds for working capital and general corporate purposes. A concurrent private placement includes purchase warrants to buy up to 3,669,725 shares at $1.09 each; exercise is subject to stockholder approval, and cash proceeds would arise only from cash exercise.
Lantern disclosed substantial doubt about its ability to continue as a going concern absent additional funding. Working capital as of June 30, 2026 included about $7.36 million in cash, cash equivalents and marketable securities; separately, Lantern believes these resources as of the supplement date, including net proceeds, will not fund operating expenses and capital expenditures for 12 months. Nasdaq notified it that listed-securities market value had been below $35 million for 30 consecutive business days; its compliance deadline is March 24, 2027.
Lantern Pharma Inc. (LTRN) hosted a live webinar on September 23, 2026, discussing the Open-Medicine AI multi-agentic AI platform for drug development. A replay is available on YouTube and the company’s investor website, and the presentation used during the webinar was furnished as an exhibit.
Lantern Pharma Inc. (LTRN) is scheduled to present the growth plan for its wholly owned Open-Medicine AI subsidiary at a live webinar on September 23, 2026, at 12:30 PM Eastern. The 45-minute session is described as including a presentation, live demonstration, and Q&A, with discussion of market opportunity, customer feedback, roadmap, subscription and enterprise licensing economics, benchmarks, and partnerships under discussion.
Open-Medicine AI’s platform was first commercialized as withZeta.ai in April 2026 for rare and aggressive cancers; ZetaOmics, a computational biology module, was released to early-access users in July 2026. The company says it is extending the platform to additional disease categories, therapeutic modalities, and stages of drug development.
Lantern Pharma Inc. reported second-quarter 2026 results and a broad business update centered on its AI-driven oncology pipeline and new AI software subsidiary. Cash, cash equivalents and marketable securities were $7.4 million as of June 30, 2026, down from $10.1 million at year-end 2025, after receiving $4.4 million in gross proceeds from a May 2026 registered direct offering.
R&D expenses fell to $1.8 million from $3.1 million year over year, and loss from operations declined about 25% to $3.5 million. However, non-cash warrant-related expense of approximately $3.6 million drove net loss higher to $7.1 million (or $0.57 per share) versus $4.3 million a year earlier. The company stated it plans to pursue additional capital raises, collaborations and other opportunities to extend its operating runway.
Strategically, Lantern established Open Medicine AI as a wholly owned software subsidiary with executed commercial licenses and subscription customers, received EMA clearance for an investigator-initiated Phase 1b/2 bladder cancer trial of LP-184, advanced LP-300’s HARMONIC trial with an amended L858R-focused protocol, and continued development of LP-184, LP-284, and Starlight’s STAR-001 across multiple oncology indications.
Lantern Pharma is an A.I.-driven oncology company with three clinical-stage small-molecule candidates (LP-300, LP-184/STAR-001, LP-284) and an ADC program, built around its RADR® and withZeta/Open-Medicine AI platforms. For the quarter ended June 30, 2026, it reported a net loss of $7.1 million versus $4.3 million a year earlier; the six‑month net loss was $10.4 million versus $8.9 million. Operating expenses fell as research and development dropped to $3.5 million for the first half of 2026 from $6.3 million, while general and administrative expenses rose modestly to $3.4 million.
Cash and cash equivalents were $6.7 million and marketable securities $0.7 million, with total assets of $8.6 million and a stockholders’ deficit of $3.2 million, driven largely by a new $7.5 million warrant liability. A May 2026 registered direct offering and concurrent private placement generated about $4.4 million of gross proceeds but also produced a non‑cash loss on warrant issuance and ongoing fair value remeasurement charges. Management discloses substantial doubt about the company’s ability to continue as a going concern without significant additional funding and plans to seek further capital, including via its ATM facility, collaborations, and grants, while continuing to progress its oncology and AI initiatives.
Empery Asset Management LP and Ryan M. Lane report beneficial ownership of Lantern Pharma Inc. common stock on a Schedule 13G. They report beneficial ownership of 1,322,551 shares of common stock, including 479,882 shares issuable upon exercise of warrants, representing 9.99% of the class. The percentage is based on 12,758,872 shares outstanding as of May 31, 2026, as reported by Lantern Pharma in a Form S-1. The warrants are subject to a 9.99% beneficial ownership limitation (the "Blocker"), so the reporting persons cannot exercise the warrants to the extent such exercise would cause them to beneficially own more than 9.99% of the outstanding common stock. All reported shares are held by funds managed by Empery Asset Management, and the reporting persons state that they may be deemed beneficial owners through their roles but each disclaims beneficial ownership of shares owned by another reporting person.
Lantern Pharma Inc. announced the formal creation of Open-Medicine AI (OMAI) as a separate company to commercialize and expand its multi-agent AI co-scientist platform, previously launched as withZeta.ai. OMAI and Lantern have executed commercial licensing agreements, approved by Lantern’s Board and consistent with the framework outlined in Lantern’s May 2026 registered direct financing. These agreements grant OMAI access to Lantern’s withZeta.ai-related models, data, algorithms, and other assets and personnel, positioning OMAI for independent growth while preserving strategic alignment with Lantern’s clinical programs and shareholders.
OMAI will advance a multi-agentic architecture first proven in oncology and rare cancer research and extend it into broader disease areas. Lantern has established Centers of Excellence in Dallas, Texas and Bengaluru, India, with the Bengaluru AI Center of Excellence created in the first quarter of 2026 to support development, refinement, and scaling of the Open-Medicine platform. Lantern cites projections that the global AI drug discovery and development market could exceed $10 billion by 2030, with oncology as the largest segment and compound annual growth rates above 30 percent. The platform includes coordinated specialist agents, multiple research modes, proprietary rare-cancer knowledge bases, and tools such as ZetaOmics™ for multi-omic analysis and generative chemistry capabilities, and is intended to pursue a dedicated funding and valuation path distinct from Lantern’s clinical activities.